Heart failure & cardiomyopathies
Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis
Authors' conclusion
In iron-deficient patients with HF with reduced left ventricular ejection fraction, intravenous FCM was associated with significantly reduced risk of hospital admissions for HF and cardiovascular causes, with no apparent effect on mortality.
Study context
- Population
- Adults with heart failure (HF) and iron deficiency, trials with ≥52 weeks follow-up
- Participants
- 4,501 adults · 3 trials
- Comparison
- Ferric carboxymaltose (FCM) vs placebo
- Outcome
- Co-primary: (i) total/recurrent CV hospitalizations and CV death; (ii) total HF hospitalizations and CV death
- Follow-up
- 52 weeks
Methodological detailsplacebo-controlled
- Placebo-controlled
Pooled result
As reported in the abstract
FCM vs PlaceboRate ratio (95% CI)P value
Co-primary endpoint 1 (CV hospitalizations and CV death); Cochran Q: 0.008
0.86(0.75–0.98)
P = 0.029Co-primary endpoint 2 (HF hospitalizations and CV death); Cochran Q: 0.024
0.87(0.75–1.01)
P = 0.076Further pooled results
Composite endpoint components
- Treatment effects appeared to result from reduced hospitalization rates, not improved survival
Original publication
Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis. Eur Heart J. Published 26 August 2023. doi:10.
Summarised from the published abstract; every number is checked against it